Bausch Health Companies Inc. (BHC) Q1 2024 Earnings Report, Transcript and Summary

Greetings. Welcome to the Bausch Health First Quarter 2024 Earnings Call. [Operator Instructions]. Please note this conference is being recorded. I would now like to turn the conference over to your host, Garen Sarafian, Investor Relations at Bausch. You may begin.

Good morning, and welcome to Bausch Health's First Quarter 2024 Earnings Conference Call. Participating in today's call are Thomas Appio, Chief Executive Officer of Bausch Health and John Barresi, Interim Chief Financial Officer. Before we begin, I'd like to remind you that our presentation today contains forward looking information. We ask you to take a moment to read the forward-looking statements disclaimer at the beginning of the slides that accompany this presentation as it contains important information. Our actual results may vary materially from those expressed or implied in our forward-looking statements, and you should not place undue reliance on any forward-looking statements. Please refer to our SEC filings and filings with the Canadian securities administrators for a list of some of the risk factors that could cause our actual results to differ materially from our expectations. We use non-GAAP financial measures to help investors understand our ongoing business performance. Non-GAAP financial measures may not be comparable to similarly titled measures used by other companies and should be considered along with, but not as an alternative to, measures calculated in accordance with GAAP. You will find reconciliations to our non-GAAP measures in the appendix of the slides that accompany this presentation, which are available on Bausch Health's Investor Relations website. Finally, the financial guidance in this presentation is effective as of today only. We do not undertake any obligation to update guidance. Our discussion today, Thursday, May 2, will focus on Bausch Health, excluding Bausch + Lomb. However, we will briefly comment on Bausch + Lomb's results announced yesterday. We will refer to year-over-year comparisons with the same period last year unless otherwise noted. With that, it is my pleasure to turn the call over to our CEO, Thomas Appio. Tom?

Thank you, and welcome to those of you joining the call this morning. We started 2024 on strong footing. Building on the momentum, we have established last year while maintaining our focus on operational excellence and our patient-centered mentality. We delivered another quarter of growth making our fourth consecutive quarter of year-over-year growth in both revenue and adjusted EBITDA. For the first quarter of 2024, revenues for Bausch Health, excluding B&L, were $1.05 billion, up $41 million or 4% on a reported basis and 5% on an organic basis. All segments delivered revenue growth on both a reported and organic basis when compared to the first quarter of 2023, led by Solta with 23% organic growth. Adjusted EBITDA for Bausch Health, excluding B&L, was $504 million, an increase of approximately 9% compared to the prior year. We also continue to make progress on our key R&D initiatives during the quarter, in line with our established timing goals. First, for Amiselimod, in April, we met with the FDA for an end of Phase II meeting and a Phase III planning meeting for mild to severe ulcerative colitis, UC. In addition, we were also pleased for Amiselimod to have been accepted for a podium presentation at Digestive Week on May 19th. Second, we completed enrollment for our second global Phase III trial for RED-C in late April, which is slightly ahead of our goal of completion by the end of the first half of 2024. And third, we are pursuing approval of CABTREO for Canada and anticipate this could occur in the second half of the year. Overall, we continue to feel good about the progress we have made on our R&D pipeline and are progressing according to the time lines we shared in February. Turning to our litigation with Norwich. On April 11, 2024, the U.S. Court of Appeals for the Federal Circuit affirmed the U.S. District Court of Delaware's August 10, 2022, judgment and also the May 17, 2023, decision that had denied Norwich Pharmaceuticals motion for modification of the court's final order. We are pleased that the Federal Circuit maintained the judgment preventing the approval of Norwich's ANDA for Xifaxan until October 2029. On April 5, 2024, we filed a patent lawsuit against Amneal pharmaceuticals following the receipt of a notice of Paragraph IV certification stating that Amneal had submitted an ANDA to the FDA seeking approval to market a generic version of Xifaxan. This action formally initiates the litigation process under the Hatch-Waxman's Act and triggers a 30-month stay of any potential FDA approval for Amneal's ANDA. As a leader in gastroenterology health, we continue to vigorously defend our intellectual property and are committed to advocating for the safety of patients who have benefited from continued access to Xifaxan. We look forward to continuing to serve our patients as every patient deserves better health outcomes and the chance to make the most of life. On the Granite Trust matter, we continue to expect the settlement with the IRS to be finalized in the coming months. As we have previously indicated, the anticipated outcome of the settlement does not have material impact on the company's results or cash flows. We continue to focus on our balance sheet and liquidity and ended the first quarter with approximately $1.5 billion of liquidity. In Q1, we repaid over $300 million of debt including the $250 million of bonds with 2025 and 2026 maturities as noted on our year-end call. Turning now to the potential full separation of Bausch + Lomb. The full separation of Bausch + Lomb continues to be a strategic priority. We continue to evaluate strategies regarding the potential full separation. With the objective of ensuring that any transaction result in two appropriately capitalized companies. The outcome at the quarter of appeals in the Norwich matter represents a significant milestone toward the full separation of B&L. Any decision regarding if and when a separation occurs or its structure will be based on and subject to an assessment of all relevant factors and circumstances. Any potential separation will also be subject to shareholder and other applicable approvals. Turning now to an overview of our segment performance for the quarter, starting on Slide 8. Salix revenue grew slightly year-over-year with reported growth of 1% and organic growth of 2% driven by Xifaxan and Relistor offset by net pricing pressure for Trulance and certain non-promoted products. During the quarter, we continued to see an increase in demand for our key products Xifaxan, Relistor, Trulance, with TRx growth of 3%, 3% and 9%, respectively. Overall, Xifaxan revenues grew 8% over the first quarter of last year, reinforcing our strategy of continuing to make investments primarily in AI-enabled sales tools, DTC advertising, which we expect will drive further growth in this important franchise this year. Turning to international. We saw solid year-over-year revenue growth during the first quarter with reported growth of 7% and organic growth of 2%. Organic growth was led by Canada, where we saw a strong performance from Contrave in the quarter. We have begun investing in DTC marketing for this product to build on this momentum. We were also pleased to receive our first public health plan listing for UCERIS Aerosol foam in Canada. Across the segment, we are also focused on driving long-term growth through investments in our promoted products and ongoing business development efforts. In Solta Medical, revenues increased by 21% on a reported and 23% on an organic basis, led by Asia Pacific. Importantly, we are pleased to see the U.S. return to growth posting 14% year-over-year growth in revenue. We remain highly focused on maintaining momentum in Asia with Thermage FLX now approved as a medical device in China and on driving growth in the U.S. and EMEA markets where we believe there is meaningful opportunity. In Diversified, we delivered a solid quarter with 3% reported and 6% organic growth over the prior year. This was led by dermatology business. As we discussed on our year-end call, CABTREO launched in the U.S. in late January and early script volume has been encouraging. We expect the new product to be a more significant contributor to the dermatology business over the remainder of the year. Neurology revenues grew slightly as we continue to capitalize on the opportunities in the market created by competitor supply constraints. While we did see volume declines in Wellbutrin and Aplenzin, as expected, improved net pricing led to higher sales of these products reinforcing our strategy in managing script profitability. This growth was offset by continued pressures on our generics business and a slight decline in our dentistry business where we expect our investments will lead to consistent growth through the remainder of 2024. Overall, we continue to focus on managing this mature portfolio of products for profitability and cash generation in a challenging competitive and pricing environment while looking for opportunities to make targeted investments where appropriate. Turning to the latest developments in our R&D pipeline on Slide 9, starting with our GI pipeline. As you will recall, in December, we announced positive top line results from our Phase II study evaluating Amiselimod and S1P antagonist for the treatment of UC. We held a Phase III planning meeting with the FDA in April and expect to meet with the international authorities, including in EMEA and Japan later this year. In the meantime, we are pleased that Amiselimod has been selected for a podium presentation on May 19th at Digestive Disease Week's Annual Conference, one of the largest and most prestigious events for gastroenterology professionals. We continue to move forward with planning for a Phase II program for Crohn's disease and expect to initiate that by the end of the year. Turning to our RED-C program with for rifaximin for reduction of early decompensation in cirrhosis. Our global program focused on assessing the efficacy of; our rifaximin SS deformulation versus placebo to delay the occurrence of hepatic encephalopathy related hospitalizations. Both global Phase III trials for this program are underway. Enrollment for the first trial, as previously mentioned, completed in December 2023, and the enrollment for the second trial completed in April of 2024, which was ahead of our goal for the first half of 2024. Together, these studies are expected to include over 1,000 patients across North America, Europe and Asia Pacific. Turning now to our aesthetics pipeline. We are pleased to have Thermage SLX and the TR4 return pad available to customers in China as of the second quarter following the approval by the National Medical Products Administration in January 2024. We plan to file an FDA submission for our next-generation Fraxel in Q2, a fractionated laser device for skin resurfacing and anticipate approval could be received in the second half of this year. Finally, our program for clear and brilliant touch, a fractionated laser device for skin rejuvenation continues to advance. We have received approvals in Australia and New Zealand this year, representing our first approval outside of the United States and remain on track for regulatory submissions in 2024 in Europe, Canada and other Asia Pacific markets. We feel good about the progress we are making on these key R&D initiatives, and we remain focused on our pipeline of new market authorization and next-generation products as we continue to grow this global durable portfolio of aesthetics products. As a leadership team, we are committed to driving growth by leveraging our existing assets, making targeted investments and executing with commercial excellence. While continuing to progress our pipeline, all with a patient-centered mentality. With that, I will turn the call over to John Barresi, who will provide further details on the first quarter performance, John?

Thanks, Tom. Hello, everyone, and thanks for joining us. We closed the first quarter with consolidated revenues for Bausch Health of $2.15 billion, up 11% on a reported basis and 8% on an organic basis over the same quarter last year. First quarter revenues for Bausch Health, excluding B&L, were $1.05 billion, up 4% on a reported basis and 5% on an organic basis over the same quarter last year with strong growth in Solta and low to mid-single-digit reported an organic growth in our other segments. Turning to segment revenue performance, starting on Slide 12 with Salix. First quarter Salix revenues increased $3 million on a reported basis to $499 million, driven by TRx growth in our key products, including Xifaxan 550, Relistor and Trulance. Revenues grew $12 million on an organic basis, reflecting the impact of divestitures and discontinuations of certain non-promoted products. Xifaxan continued to represent over 80% of Salix segment revenues this quarter and saw strong growth in underlying demand. Xifaxan revenues in Q1 increased 8% compared to the prior year period. Retail prescriptions grew 3% in Q1 versus the prior year. We saw another quarter of solid growth in TRx for IBS-D and the long-term care channel for HE. Extended units grew 4%, which included double-digit growth in nonretail units attributable to outpatient clinics. Relistor delivered 10% growth over the prior year period with solid TRx growth of 3% and a benefit from favorable net pricing relative to Q1 of the prior year. Trulance revenues declined 7% year-over-year as solid TRx growth of 9% compared to Q1 of last year was offset by net pricing pressure. We also continued to experience meaningful net pricing pressure in our non-promoted portfolio in this segment. International revenues were $265 million during the quarter, an increase of 7% on a reported basis and 2% on an organic basis compared to the prior year period. Organic growth was led by Canada. The LatAm and EMEA were flat on an organic basis LatAm was impacted by the timing of government purchases with private channel sales showing growth, while in EMEA, growth in key promoted products was offset by the effects of competition on certain of our nonpromoted products. Solta Medical revenues were $88 million during the first quarter, an increase of 21% on a reported basis and 23% on an organic basis over the prior year period. Solta's growth was led by China and South Korea, and to a lesser degree, the remainder of Asia Pacific. Importantly, the U.S. returned to growth this quarter with a 14% increase in revenues over the prior year and we are continuing to invest in our sales force and related tools to drive sustainable growth in this key market. Diversified revenues were $202 million during the first quarter, an increase of 3% on a reported basis and 6% on an organic basis compared to the prior year period. In Dermatology, revenue grew by 16% on a reported basis and 25% on an organic basis in the quarter over the prior year period, as we continued to focus on returning this business to consistent growth. Growth in the quarter benefited from favorable net pricing comparisons quarter-over-quarter, which we expect will moderate for the remainder of the year, while volumes for our nonpromoted products continue to be pressured. As Tom noted, we are pleased with the early response in the market to CABTREO since its late January launch and expect it to become a more meaningful driver of growth in our dermatology business as the year progresses. Neurology revenues grew slightly, posting a 1% increase year-over-year as we continue to benefit from competitor supply disruptions, although not at the same levels that we saw in Q4 of 2023. Wellbutrin and Aplenzin revenues grew despite lower volumes as we continue to execute our strategies to improve overall profitability in this business. While dentistry revenues declined modestly in the quarter compared to Q1 of last year, we continue to invest in this durable business for the long term and expect the investments we are making in the sales team and related tools to return this business to growth through the remainder of 2024. As shown on Slide 16, Bausch + Lomb revenues were $1.1 billion during the first quarter, up 18% on a reported basis and 11% on an organic basis compared to the prior year with growth across all Bausch + Lomb segments, key product franchises and geographies. Turning to the first quarter P&L on Slides 18 and 19. First quarter consolidated adjusted gross margin was 71.2%, 110 basis points higher compared with the prior year. For Bausch Health, excluding B&L, adjusted gross margin for the first quarter was 79.5%, approximately 20 basis points higher than last year's first quarter. At B&L, adjusted gross margin was 63.2% for Q1 of 24 compared to 60.0% for Q1 of 2023, driven primarily by product mix, including the impact of Xiidra. Consolidated adjusted operating expenses for the first quarter were $916 million, an increase of $82 million. For Bausch Health, excluding B&L, adjusted operating expenses decreased by approximately $16 million compared to the first quarter of 2023. Higher A&P driven by investments in the dermatology and dentistry businesses and R&D were offset by lower G&A expenses as we continue to focus on cost management. We expect A&P increases to moderate over the course of the year as we begin to annualize our investments in selling and marketing for Salix. B&L reported an increase of $98 million in adjusted operating expenses due primarily to increased selling in A&P, driven by the addition of Xiidra and product launches, including Miebo. Consolidated adjusted R&D expense for the quarter was $150 million, an increase of 5% compared to the prior year and represented 7% of product sales compared with 7.4% for the prior year period. For Bausch Health, excluding B&L, R&D expenses of $69 million increased by approximately $2 million for the first quarter as compared to the same quarter last year. This increase is in line with our expectations as we continue to invest in our GI and aesthetics pipeline. First quarter consolidated adjusted EBITDA attributable to Bausch Health was $665 million, an increase of $77 million or 13%. Adjusted EBITDA for Bausch Health, excluding B&L was $504 million for the quarter, a 9% increase from $462 million in the first quarter of 2023. Turning to cash flow. On a consolidated basis, Bausch Health generated $211 million of operating cash flow and $181 million of adjusted operating cash flow in the first quarter. For Bausch Health, excluding B&L, adjusted operating cash flow was $133 million for the first quarter compared to adjusted operating cash flow of $94 million for the first quarter of 2023, with the changes primarily reflecting improved business performance. As we've discussed in prior quarters, as a result of the accounting treatment for the senior notes issued as part of our 2022 debt exchange, a portion of our cash interest payments are classified as financing cash flows. Adjusted cash flow includes payments of the full contractual interest as well as adjustments for the payment of separation costs, business transformation costs, and litigation and other matters net of insurance proceeds. Now let's turn to our balance sheet on Slide 19. We continue to prioritize liquidity management and the delevering of our balance sheet. In the first quarter, we reduced our debt for Bausch Health, excluding B&L by $307 million, while debt net of cash decreased by $110 million. We continue to evaluate alternatives to reduce our overall leverage while also focusing on our maturity profile. As we discussed on the year-end earnings call, in January 2024, [indiscernible] $250 million in principal value of 2025 and 2026 maturities through open market repurchases, capturing approximately $12 million of discount in the process. We also repaid $56 million of additional debt consisting of mandatory term loan amortization and repaying a portion of our AR facility. At the end of the first quarter, Bausch Health, excluding B&L, had $325 million outstanding under our AR facility and had no outstanding borrowings and approximately $950 million of availability under our revolving credit facility. As shown on Slides 20 and 21, total debt for Bausch Health, excluding Bausch + Lomb at the end of the quarter was $16.1 billion, which consisted of approximately $14.8 billion of restricted debt issued by Bausch Health, excluding B&L, and approximately $1.3 billion of unrestricted debt, which includes the $1 billion of senior secured notes issued by the unrestricted subsidiary created in the third quarter of 2022 and and the $325 million drawn under our AR facility. Excluding B&L debt, approximately 85% of our debt is fixed and approximately 70% of the company's debt on a consolidated basis is fixed. We ended the quarter with approximately $1.5 billion of liquidity, which includes approximately $431 million of cash and $950 million of availability under our revolving credit facility. We are focused on strengthening our balance sheet, including evaluating and utilizing as appropriate various tools and strategies based on the provisions of our existing debt agreements, along with our existing liquidity to manage both our maturity profile and our overall leverage. Turning to guidance. We are maintaining our guidance for the full year 2024. For Bausch Health, excluding B&L, we continue to expect revenue of $4.7 billion to $4.85 billion, with organic growth of 2% to 5%, along with adjusted EBITDA of $2.36 billion to $2.46 billion and adjusted operating cash flow in the range of approximately $775 million to $825 million. I'll now hand the call back to Tom.

Thank you, John. We continue to build on our strong global portfolio of businesses and remain highly focused on delivering against the objectives we laid out last quarter, including driving a results-oriented culture of accountability, delivering on our revenue, adjusted EBITDA and adjusted operating cash flow commitments. Executing with operational excellence and cost-focused mindset across the enterprise, intensifying our focus and operating rigor behind R&D and business development and continuing to evaluate strategic alternatives, achieving the full separation of B&L remained a priority. These priorities helped support our ambition of being a globally integrated health care company trusted and valued by patients, health care providers, employees and investors as we relentlessly drive to deliver better health outcomes. I would also once again like to extend my thanks to the entire Bausch Health team for their hard work. They have worked tirelessly and are all in to position our business for the long term. Every patient deserves better health and the chance to make the most of life. This drives us on with urgency and efficiency to deliver the products patients need most to enrich their lives. On behalf of the entire Bausch Health team, I thank you for your interest and support of our company. With that, we will now take questions. Operator, please open the line for Q&A.

[Operator Instructions]. Your first question is coming from Glen Santangelo from Jefferies.

Tom, just a couple of quick ones for me. You reiterated a number of times that you remain committed to the full separation and you highlighted sort of the Norwich decision as being a significant milestone. What are the milestones or major milestones might exist? And then as you think about the strategies for a full separation, is it in your mind? Is the tax-free spin still the way to go? Or the -- or are there other strategies that you might be evaluating? And then maybe I just had a quick follow-up on the balance sheet.

Okay, Glen. Thanks for the question. Clearly, of course, the Norwich appeal decision is an important milestone. So we are really happy about that and really pleased with the outcome. But as you know, there's multi-factors here that we need to consider. So as we take a look at it, really the timing of the potential distribution, the most fundamental point is making sure that we have to appropriately capitalized companies. So as we look at it, as you know, there's moving parts when it comes to our balance sheet, when it comes to other things in terms of litigation or what have you. So really kind of thoughtfully going through it and progressing through what needs to be done. What I would say is when we look at it, making sure when we take a look at the full separation, it is a priority for us. As you can see on our priorities for 2024, it is a key priority to the full separation of B&L. And basically, as we've talked about before, making sure, again, we're totally in line with appropriately capitalized two companies.

And Tom, maybe just to follow up on that point on the balance sheet. When you think about the leverage on RemainCo, we've gotten a lot of pushback from investors highlighting the leverage related to the RemainCo post the spin. How do you think about what the appropriate leverage ratio might be? I mean, you haven't sort of commented in a while on any of those leverage targets, but it seems you remain committed towards using various tools and strategies as you put it to kind of maybe work that debt level down. So any sort of thoughts on how we should think about that through the balance of the year?

Yes. Look, Glen, what I'll do is let me just take the first point of that, and then I'll give it to John. But overall, as you saw this quarter in the last 4 consecutive quarters, my focus -- one of my key focus is really driving growth, driving performance. Of course, that always helps us be able to continue to retire debt. So we have a really healthy business globally. And as you saw the results for this quarter, both in the U.S. and internationally, the business is growing and growing broadly. You saw the performance of Solta, we really feel really great about the performance and the return to the performance in the U.S. of growth. So we have a really -- the business is healthy and is doing well. Diverse portfolio of products. And then clearly, we're executing on our R&D pipeline and investing appropriately. So as we look at all those things, we're positioning ourselves as we look at our balance sheet and what we can do. I'll hand it over to John to speak specifically on the balance sheet.

Glen, it's John. Thanks for the question. Yes, to the point of how do we think about a leverage target, I think it comes back to what Tom said a minute ago, right? Fundamentally, we're focused on two appropriately capitalized companies. And I think that's -- there's no one binary point measure for that. It's really about balancing our leverage with our maturity profile. And as we've said, we're very focused on managing both of those effectively. We have a lot of tools at our disposal. As Tom said, we're focused on growing the business in a very cash-generative business. We're guiding to $775 million to $825 million of adjusted operating cash flow this year. We have a really broad diverse footprint, both product-wise and geographically, and we think there's value in that. We're working on the pipeline, as you heard and Tom's prepared remarks earlier. And we'll use all of the tools that we have available, whether that's to do open market repurchases, we've done debt exchanges in the past. We've done asset sales in the past. We have the BLCO stake of approximately 8% at our disposal and $1.5 billion of liquidity. So it doesn't directly answer your question of a point target, but those are all the things we think about as we think about managing both the maturity profile and leverage.

Your next question is coming from Michael Nedelcovych from TD Cowen.

Great. Thank you for the question. As has been noted, I think this is the first time, at least in the recent past that management has explicitly connected that look for Xifaxan to the likelihood of completing the full separation of Bausch + Lomb. So that begs the question of when Xifaxan's outlook will be secure, if we just consider the Amneal challenge and take the 30-month stay at face value, that would mean persistent uncertainty until almost 2027 which puts us right at the doorstep of full generic competition for Xifaxan. So I'm wondering how will it be possible to complete the Bausch + Lomb separation under those circumstances?

Yes, Michael, thanks for the question. It's -- I'm glad you asked it because I've seen a lot of things going back and forth in the press regarding Amneal. So firstly, I just want to make sure we're clear is that Xifaxan is a huge product. Everybody looks at it. They're interested in it, the performance is great, and it continues to perform and grow. You saw the quarter where we round up with highest TRxs on record, all-time high. So it's doing well, and it's growing and the investments we're making behind it. So Paragraph IVs, the Amneal issue was not unexpected. What I think the most important thing here is, number one, is that the patents issue here are not the same. That were in -- on the Norwich case. So there's new patents. So this is -- and we have a legal team. I am really in a great position to have such an outstanding legal team who is looking at it and working on it really, really hard. So the Amneal issue as we look at it, many patents there to consider as we work it through. So I cannot speculate again on what the strategy will be. But clearly, it wasn't that it was a surprise, and we have a team that's working on it. So I don't really see that as we move forward as situation that we're going to continue. Again, we'll probably see -- we could see others, but the time frame that it has, we're going to work it real hard.

May I ask a follow-up?

Sure.

Are you preparing for Norwich to file a new ANDA just for the IBS indication, you suggested you may see others just now. And is there anything in the settlement with the other generics companies that would prevent them from doing the same thing?

Yes. So right now, as you know, we just got the ruling, the affirmation of the denial of the motion, Norwich is off the market until October of 2029. This is a large milestone for us. I can't speculate what Norwich will do in the coming weeks or months. What I would say is, we feel we have a great legal team who's looking at it and monitoring it, and we'll see how it works out.

Your next question is coming from Douglas Miehm from RBC Capital Markets.

First question, just in the past, the company has discussed whether or not in its approach to the distribution or the separation you would comment on whether it potentially would be a return of capital or butterfly. Is there anything that you can update us on as to the potential approach that the company may take in the event you do pursue the separation?

Yes, Doug, thanks for the question. Yes, we have talked about that in the past. But at this point, no decision has been made. What I would say is we still are focused on making sure it's deemed a tax-free to shareholders. So continuing to keep all options open and evaluating it as we progress.

Okay. And then second thing, just maybe you could give an update on the stock drop situation. I know you've been trying to resolve that, but we are getting close to a court date, I believe, on part of that? And then finally, I know this is really not that important or material. But why is the IRS situation taking so long relative to when you thought you may be able to resolve that?

Doug, the IRS, of course, is moving slow. I'll ask John to take that, and then I'll come back to your question on the opt out.

Doug, yes, I think we'd love to have the settlement official and behind us as well. We're working that with the IRS as expeditiously as we can. It's a really complicated matter as we've disclosed in the past, and we currently still expect that the settlement will not have a material impact on our results or on our cash flows. It's a matter of getting through the process, I think, at this point.

Yes. And then I'll just take the second -- the first part of your question regarding the opt out. We've consistently knew that at some point, we're going to have a trial date. The team, again, as I pointed out earlier, the legal team has been working on this. As you know, we settled the class. We had -- we've also settled 16 out of 37 opt-out actions have either been settled or dismissed. The total remaining opt-out actions pending are 21. What I would say is we have had success on summary judgment on some of the claims have been narrowed. And we'll continue to work on it. And we have, what I would say, is a strong litigation team very focused on this, and we'll see how it progresses as we move closer to a trial date.

Your next question is coming from Umer Raffat from Evercore.

Maybe a couple here, if I may. First, is there any regulatory body, U.S. or ex U.S. or a creditor that needs clarity on Xifaxan within the 24 months post separation. Is that an important gating factor for potential investors? That's point number one. And number two, for some of your debt liabilities coming up in '25 or so what are the plans? Are you intending to go down very aggressive path? And then finally, do you envision any possible scenario where the spin has to be held off completely to take care of the amount of debt as well as the Xifaxan situation.

Yes, Umer. Thanks for the question -- the questions. Right now, let me just give the debt issue to John, maybe he can comment on that.

Yes, Umer, I think we're certainly focused on our '25, '26, all of our maturities really in our leverage or '25 and '26. I'll go back to what I said in one of the earlier questions, right? We have a number of tools at our disposal. We have $1.5 billion of liquidity. We have the ability to generate significant cash flow in a very cash-generative business and we have the broad portfolio that we have with a number of valuable assets, including the stake of BLCO that we can distribute while staying above that tax-free distribution threshold. And so we're looking at all of those as ways to manage our maturities. Beyond that, I won't comment on any specific things that we may do other than to say we've done a combination of all of these things in the past, OMRs, debt exchanges, asset sales, and we'll continue to look at all of those levers.

Yes. And Umer, I'll take the first point of your question. I'm not aware of any specific Xifaxan regulatory body in the U.S. or ex U.S. What I would say is that I've said many times is really making sure we have two appropriately capitalized companies. And to the last part of your question is our priority is the full separation of B&L. So as we work through it, as I said earlier, some -- on my prepared remarks and into earlier questions is really, there's a progression as we work it through and we'll keep everyone updated as we work it. But I really appreciate the question. Thank you.

Your next question is coming from Chi Fong from Bank of America.

This is Chi on for Jason Gerberry at BFA. I guess on the first one, now that you secured the Norwich ruling, has the company been in discussion with claimants in the fraudulent conveyance manner about a potential settlement? And I have a couple of follow-ups after this.

Yes. Chi, basically, I can't comment on what have we been in discussions. I can't really discuss that at this time. But again, we're always open to discussions and looking at the options. You had a follow-up question?

Yes. A couple of follow-ups. One on -- the first one is on SG&A. So as we look at 1Q, the spend ratio looks a little high in the mid 30s. I'm wondering if there's any 1Q seasonality to drive the ratio higher than usual? Or if not, how do you see that SG&A spend ratio evolving in the coming years?

Yes. Chi, are you looking consolidated?

Yes, consolidated.

Yes. So I think BLCO spoke a little bit to this yesterday as well. There has been a significant A&P investment on the BLCO side supporting both Xiidra and some of their product launches like Miebo. And that is on a consolidated basis, I think the biggest driver there.

Okay. Got it. And my last one is on the pipeline. On Amiselimod, were there any surprising points of feedback from the end of Phase II meeting? And as you come up with this FDA meeting, I understood that you still have discussions with international agencies. But do you have any early thoughts on your Phase III strategy as you look to capture the entire spectrum of mild to moderate UC. And then I think you have to mention that you're still considering a Phase II trial in Crohn's. I'm curious if the recent Phase III trial of -- Phase III [indiscernible] Crohn's, also you're thinking about continue investment in Crohn's there?

Yes, Chi, thank you for the question on the business and the pipeline. I really appreciate that. As you know, really focused on the pipeline RED-C as we had fully enrolled these two trials and are really interested in getting them completed. When we look at Amiselimod, we are really happy that we were accepted on the podium at DDW, which is coming up later this month and presenting our data. As you know in our press release, we were really pleased with the data that we had on our Phase II, very large Phase II trial. Our strategy here is the meeting with the FDA. It went well, and we're progressing on this. We -- from a UC perspective, when we look at it, we see this market very large, and we think we have a product that can compete here very nicely. So really, by the time we're ready to launch, we're probably looking between a market of $7 billion to $8 billion. So really a great growth driver for us in the back half of the decade. Looking at the Phase III trial, hoping to get that up and running later this year or the beginning of 2025. On Crohn's, again, as you know, this is a real large market. We would really love to be participating here. We think we have, based on our data, what we've seen out of the UC trial, that we're going to run a Phase II -- plan a Phase II moderate to severe in CD. And again, over $19 billion market and we think we have a drug that can compete. Now of course, yes, you mentioned that the failures of S1Ps in Crohn's, but when we look at this trial in Phase II and how we're going to structure it, we think we can have some success. Thank you for the question. I really appreciate the question on the pipeline.

Your next question is coming from David Amsellem from Piper Sandler.

So just a couple of questions. Long-term focused questions. In terms of your rifaximin business, how are you thinking about erosion of the franchise once you do see generic competition materialize. And I guess what I'm trying to get at is what are your expectations surrounding the next-generation rifaximin product as a means of cushioning some of the impact of generic competition. So that's number one. And then number two, I know you alluded to it on the prior question, but on Amiselimod, do you have a sense based on your own market research, how you're thinking about the sales potential here in the context of an increasingly crowded market with other agents that have novel mechanisms such as the TL1A? How do you think about sales potential for Amiselimod to the extent that you commercialize it?

David. So firstly, again, thanks for the question on the pipeline. I'm really glad that the questions are on the pipeline and on the business today. RED-C, I just -- as I look at this program, when I took over as CEO, one of the things I worked with our Head of R&D is to really accelerate this trial. Clearly, you mentioned with the Xifaxan going off patent, how do we fill that gap. When we look at where we're going to get to and the timing of launch for RED-C, we're progressing it and we're really trying to execute with excellence to get there prior to Xifaxan going off patent. And also, I'd like to point out here, we have -- this is a global program. We have global rights. This is a new formulation. So, this really opens us up, as you know, Salix, long history in the U.S. in gastroenterology and liver. Now, this really gives us a platform globally with RED-C. We just kind of put some numbers around it, just when we look at the -- just in the U.S. alone. Again, this is a prevention. This is going towards prevention. So the pool is much larger that we can look to in the U.S. So if you just say the cirrhotic patients in the U.S. today were around 800,000. And then if you take out the patients that have [indiscernible] today, given that it's prevention, now you're at about 650,000 and 600,000. And if you look at Xifaxan today, you have 100 -- and so you have over 150,000 [indiscernible], we're treating only 25% of that. So if you look at the pool that we have to of patients on a prevention. And then that's just in the U.S. If you then model that out to international markets, and building a GI liver portfolio in the international space. As we talked about our international business is we got -- we have really great platforms around the world. And I see a great opportunity here as we -- of course, you need the data, but it's really exciting what we're on the RED-C. When we take a look at your second question is, as I talked about, Amiselimod I'm really excited about it as well. Looking forward to getting into our Phase III -- Phase III program. And again, the R&D team real focus because we know we're losing Xifaxan. So where can we close these gaps? One of them is with RED-C, another can be with Amiselimod. What I would say also is our BD team. I think one of the things that we have done over the last 2 years, we have built a really strong BD team. And so therefore, we are looking to be able to find some assets that we can bring in to slot into our businesses in the United States and in international that can close the gap as well. So this is a real priority for us. That's why you see it in our priorities of how to really accelerate the pipeline, but also from a BD perspective, we have screened a number of assets, and we have to be really pedantic about it to make sure that we bring in the right asset and making sure from -- does it fit? What is the cost? And also remember, one of our pillars is making sure that quality -- the quality of the product. So as we do diligence, we're making sure that the products that we can bring into this company are high quality and continue to build a great pharmaceutical company. But thank you for the question. Really appreciate it.

Your next question is coming from Leszek Sulewski from Truist Securities.

I actually do have a couple of follow-ups on the pipeline. So on your RED-C program with enrollment on both trials now complete, can you handicap the time line for top line results? And what would you disclose data from one study or both together? And is there a possibility you would release preliminary data? And then secondarily, on CABTREO, is there any initial feedback from prescribers regarding the trends that you're seeing? And how sizable ultimately is this market within the category and also your plans for launching into Canada once approved. And then third, on Thermage, what is the market strategy to -- or go-to-market strategy in China? And how big is the opportunity there for you in that product launch?

Thanks for the question. So I'll take the first one on RED-C. Again, trying to make sure that we have RED-C prior to the loss of Xifaxan would be key. Right now, hoping we get data in late 2025, early '26, and we'll see, again, making sure that, that trial is on track and can deliver and then, of course, being able to file it and get it registered not only in the U.S. but around the world. So -- that's where I see the time frame really comes down to making sure that, again, going back to the previous question on filling our gap and knowing Xifaxan is going generic in 2028. CABTREO, we're excited about it. We love the product. The R&D team has done a wonderful job here. We think it's a great product for acne. The team is really all in and focus on driving this. If I just look at the script growth, it's ahead our goal that we had set. Again, a crowded space, but really this is a great product. And the feedback from our customers and patients has been really strong. What I would say also is it's in the early stages. We launched it. And then we actually launched it ahead of having samples. So we're really excited now that we have the samples coming on. We also have the DTC campaign that will happen coming up in the next few months. So this is really a focus for our derm business and the R&D team has done an outstanding job here of bringing a great product to the market for patients. Thermage FLX in China, again, I am really excited. As you know, I lived in China for many years. So I know this market extremely well. I think we have an outstanding opportunity. As you saw the performance of our business. This quarter has been -- was outstanding led by China, led by Asia Pacific as well. We are looking at our strategies on Thermage. I would say we just had the launch meeting last week, and it went extremely well. Our strategy here is, again, if you look at the opportunities in China today, and you hear a lot about the economics of China. In terms of post-COVID, you hear a lot about the property market. But if you look at the patients that we target and you look at the -- even though in China, the COVID had an impact, but there was also a lot of savings that took place. So they weren't traveling, weren't doing many things. So there, we see that our patient population has the opportunity and the economics to use our products. And what you see also in China, you see that noninvasive treatments are very, very popular. Solta has a great name in China. We have a great brand. So now having it approved by the [indiscernible] as the first RF device to be approved, we think we have a great opportunity. We're building our team. In fact, I'm going to be in China in the next couple of weeks to talk to the team, make sure we have the strategies in place and then executing those strategies accordingly. But I lived there for many years, so I'm really confident we are going to have a real successful business in China. And we -- I'm piggybacking on it, we already do, but we're just going to grow more on that. Thank you for the question.

We've reached the end of the question and answer session. I'll now hand the conference back to Chief Executive Officer, Thomas Appio, for closing remarks. Please go ahead.

Yes. What I would just try to say is, to everyone on the call, I really appreciate everyone's questions today, and really making sure that we're looking at the performance of our business and what the pipeline is and what the future can be. So I really thank everyone for joining today. As I said many times, we had a solid Q1 fourth consecutive quarter of growth. I really want to build on this momentum in Q2. I would also say is the team here at Bausch Health is all in. We know what we need to do and really making sure we execute with excellence. So making sure you saw the priorities, what our priorities are, delivering our commitments and continuing to position this company for the future. And what I -- lastly, I'd like to say is we look forward to keeping you all updated and really thank you for your interest and the support of our company. Really appreciate it, and have a great day.

Thank you, everyone. This concludes today's event. You may disconnect at this time, and have a wonderful day. Thank you for your participation.